Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
8
×
boston blog main
clinical trials
8
×
fda
8
×
life sciences
national blog main
boston top stories
biotech
deals
national top stories
alnylam pharmaceuticals
patisiran
rna interference
san francisco blog main
alexion pharmaceuticals
drugs
hereditary transthyretin amyloidosis
investing
new york blog main
new york top stories
onpattro
rare disease drugs
roche
san diego blog main
san diego top stories
san francisco top stories
acute hepatic porphyrias
akcea therapeutics
akin akinc
akouos
allopregnanolone
aminolevulinic acid
amyotrophic lateral sclerosis (als)
andrew fire
astellas pharmaceuticals
autoimmune disorders
avapritinib
biotech ipos
blueprint medicines
boehringer ingelheim
What
drug
8
×
fda
medicines
pharmaceuticals
approved
medicine
alnylam
approval
candidate
developing
disease
ipo
muscle
pharma
rnai
roche
specifically
team
therapeutics
affects
afternoon
ago
alnylam’s
alternative
americans
autoimmune
blueprint
brexanolone
brings
cancer
caught
causing
company
currently
date
deal
depression
devastating
dicerna
disorder
Language
unset
Current search:
fda
×
drug
×
boston
×
" clinical trials "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug